Novartis to present Kisqali data and more at ASCO meeting

Basel, Switzerland-based pharma giant Novartis (NOVN: VX) has provided an outline of the data it intends to present at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

Data will also be presented at the European Hematology Association (EHA) annual meeting in mid-June, in Amsterdam, Netherlands.

The results will feature overall survival data from MONALEESA-7 with Kisqali (ribociclib), plus endocrine therapy, in certain women with HR+/HER2- advanced breast cancer.

Novartis will also unveil primary results of the GEOMETRY study of capmatinib, an investigational MET inhibitor, in development or certain people with advanced non-small cell lung cancer (NSCLC).

In addition, there will be five-year efficacy and safety updates for Tafinlar+Mekinist (dabrafenib/trametinib) in people with BRAF V600-mutant unresectable or metastatic melanoma.

Both congresses will highlight updates on Tasigna (nilotinib), with treatment-free remission trial updates after more than 3.7 years of follow-up, as well as the investigational compound asciminib in chronic myeloid leukemia (CML).